UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number including area code)
(Registrant’s former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 12, 2022, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release, dated May 12, 2022 | |
| 104 | Cover Page Interactive Data File (embedded with Inline XBRL document). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEUROONE MEDICAL TECHNOLOGIES CORPORATION | ||
| Dated: May 12, 2022 | ||
| By: | /s/ David Rosa | |
| David Rosa | ||
| Chief Executive Officer | ||
2
Exhibit 99.1
NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., May 12, 2022 (PR Newswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter of fiscal year 2022 ended March 31, 2022.
Second Quarter and Recent Business Updates
| ● | Evo® sEEG electrode first commercial order is in inventory and ready to ship pending FDA clearance for less than 30 day duration of use. The Evo sEEG electrode was already 510(k) cleared for temporary (less than 24 hours) use. |
| ● | Filed appeal with the FDA regarding their decision related to the Company’s request for clearance for less than 30 day use of NeuroOne’s Evo® sEEG Electrode. Appeal meeting between NeuroOne and the FDA was held on April 14th, 2022. |
| ● | Participated in Zimmer Biomet’s physician advisory board meeting with prominent neurosurgeons to perform usability testing of Evo sEEG implant accessories. |
| ● | Initiated the process to qualify a second source to manufacture electrodes for Evo® Cortical and sEEG product lines to increase manufacturing capacity and reduce supply risk for both product lines. |
| ● | Initiated cost reduction program for cable assembly. |
| ● | Exhibited our Evo Cortical electrode product family at the University of Minnesota Neuromodulation Symposium and presented at the Gordon Research Conference 2022 Neuroelectronic Interfaces Meeting. |
| ● | Announced positive five-year bench top results in stimulation testing of electrodes designed for use in spinal cord stimulation for patients suffering with chronic back pain. |
| ● | Completed prototypes for RF ablation system as well as planning phase with our hardware partner RBC Medical Systems which remains on schedule to submit to FDA in the first quarter of calendar year 2023 for commercial clearance. |
| ● | Appointed Maria Vomero, PhD., a prominent scientist and expert in thin film electrode technology to drive the Company’s spinal cord stimulation program, further strengthening the development team. |
| ● | NeuroOne featured on “The Claman Countdown,” an American financial program airing on the Fox Business Network. |
| ● | Presented at the 34th Annual Roth Capital Partners Conference and the Oppenheimer 32nd Annual Virtual Healthcare Conference. |
Dave Rosa, CEO of NeuroOne commented, “In September 2021, NeuroOne received FDA 510(k) clearance for our Evo sEEG product line for less than 24 hour use. Although the FDA did not provide clearance for longer term use for our sEEG product line, the Company remains confident that the product met ISO 10993 “Biological Evaluation of Medical Devices - Part 12 and Part 18” requirements for biocompatibility which was the basis of the Company appealing the FDA decision. We appreciated the FDA’s willingness to hear our appeal which occurred on April 14th, 2022. We continue to remain ready to fulfill our initial stocking order to Zimmer Biomet upon an FDA clearance for less than 30 day use. Additionally, the development of our RF ablation electrode and hardware remains on schedule as we expect to complete system prototypes by the end of the third calendar quarter of 2022. We are still targeting submitting for 510(k) clearance for RF ablation in early calendar year 2023. Cost reduction programs are underway for our cable assembly line, next generation connector and validation of a new electrode supplier in order to ensure the ability to meet supply requirements to Zimmer Biomet. Our team remains enthusiastic and determined as we make progress across a number of key commercial and product development objectives for 2022.”
Upcoming Targeted Milestones
| ● | Evo sEEG Depth Diagnostic Electrode |
| o | FDA decision on Company’s appeal regarding the FDA’s denial for clearance of the Evo sEEG product line for less than 30 day use. |
| ● | Qualification of second source for manufacturing of the Evo Cortical and sEEG electrode product lines. |
| ● | Completion of validation of new cable assembly providing significant cost reduction for the specific component. |
| ● | Completion of design verification to extend the shelf life for cortical electrode product line to 3 years and sEEG product line to 2 years. |
| ● | RF Ablation system |
| o | Generator prototype expected by the end of the third calendar quarter of 2022. |
| o | Completion of additional feasibility testing planned on sEEG RF probe, temperature accessory, and RF connection box expected in September 2022. |
| o | Submit 510(k) application to the FDA in early calendar year 2023. |
| ● | Completion of physician advisory board for spinal cord stimulation program. |
2
| ● | Partner with research organization to develop electrode for new clinical indication. |
| ● | Chronic Use Electrode |
| o | Report additional accelerated aging test results for chronic stimulation electrodes. |
Second Quarter of Fiscal 2022 Financial Results
Product revenue was $37,000 in the second quarter of fiscal 2022, compared to product revenue of $18,000 in the second quarter of fiscal 2021. Collaboration revenue was delayed in the second quarter of fiscal 2022 due to the FDA decision, compared to collaboration revenue of $20,000 in the second quarter of fiscal 2021. Collaboration revenue was derived from the Zimmer Development Agreement and represented the portion of the upfront initial development fee payment eligible for revenue recognition as of March 31, 2022.
Total operating expenses in the second quarter of fiscal 2022 were $3.0 million, compared with $2.4 million in the same period of the prior year. R&D expense in the second quarter was $1.8 million, compared with $1.3 million in the same period of fiscal 2021. SG&A expense in the second quarter of fiscal 2022 was $1.2 million, compared with $1.1 million in the prior year period.
Net loss was $3.1 million for the second quarter of fiscal 2022, compared to a net loss of $2.4 million in the second quarter of fiscal 2021.
As of March 31, 2022, the Company had cash of $12.9 million, compared to $16.2 million at December 31, 2021 and $6.9 million at September 30, 2021, our fiscal year end.
The Company had no debt outstanding at March 31, 2022.
Conference Call Information
Event Date:
May 12, 2022 - 4:30 PM Eastern Time
Participant Dial In:
Toll Free: 877 407 8293/ +1 201 689 8349
3
Live Webcast:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=MBrdTO6j
Phone Replay:
877-660-6853 / +1 201-612-7415, Access ID: 13729644; available through May 26, 2022
Webcast Replay:
Available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the development of the Company’s ablation electrode technology program, applications for, or receipt of, regulatory clearance, the timing and extent of product launch and commercialization of our technology, expected negotiations with Zimmer Biomet, clinical and pre-clinical testing, what the future may hold for electrical stimulation and NeuroOne’s potential role, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes may not be ready for commercialization in a timely manner or at all, whether due to supply chain disruptions, labor shortages, the impact of COVID-19 or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds; the risk that the COVID-19 pandemic will continue to adversely impact our business; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the order of a physician”
Contact:
800-631-4030
ir@n1mtc.com
4
Cover |
May 12, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | May 12, 2022 |
| Entity File Number | 000-54716 |
| Entity Registrant Name | NeuroOne Medical Technologies Corporation |
| Entity Central Index Key | 0001500198 |
| Entity Tax Identification Number | 27-0863354 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 7599 Anagram Dr. |
| Entity Address, City or Town | Eden Prairie |
| Entity Address, State or Province | MN |
| Entity Address, Postal Zip Code | 55344 |
| City Area Code | 952 |
| Local Phone Number | 426-1383 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | NMTC |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |